Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nereus Pharmaceuticals, Inc.
This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues. There are indications of advantages in combining vascular disrupting agents with standard agents in the treatment of advanced non-small cell lung cancer (NSCLC).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and females ≥ 18 years of age
ECOG performance status ≤ 1
Pathologically or histologically confirmed advanced non-small cell lung cancer (unresectable Stage IIIb or IV) that has progressed after treatment with at least one chemotherapy regimen; measurable disease is not required for enrollment into this trial
All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to Grade ≤ 2
Signed informed consent
You may not be if
Administration of certain chemotherapy, biological, immunotherapy, radiation therapy, surgery or investigational agent within specified time frames
Significant cardiac history
Prior treatment with tumor vascular disruptive agents
Seizure disorder
Brain metastases
Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy
Known infection with human immunodeficiency virus (HIV), or active hepatitis A, B, or C
Patients with a prior hypersensitivity reaction to product components
Pregnant or breast-feeding women.
Concurrent, active second malignancy for which the patient is receiving therapy, excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix
Unwilling or unable to comply with procedures required in this protocol
